Tiexin Wang

Tiexin Wang

Auto-generated profile, based on publicly available information

Tiexin Wang

Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2019 in Antibodies
Verified
Journal Article
Open access
PDF file
QWQiong Wang
Qiong Wang
YCYiqun Chen
Yiqun Chen
JPJaeyoung Park
Jaeyoung Park
XLXiao Liu
Xiao Liu
YHYifeng Hu
Yifeng Hu
MBMichael J. Betenbaugh
Michael J. Betenbaugh
With the current biotherapeutic market dominated by antibody molecules, bispecific antibodies represent a key component of the next-generation of antibody therapy. Bispecific antibodies can target two different antigens at the same time, such as simultaneously binding tumor cell receptors and recruiting cytotoxic immune cells. Structural diversity has been fast-growing in the bispecific antibody field, creating a plethora of novel bispecific antibody scaffolds, which provide great functional variety. Two common formats of bispecific antibodies on the market are the single-chain variable fragment (scFv)-based (no Fc fragment) antibody and the full-length IgG-like asymmetric antibody. Unlike the conventional monoclonal antibodies, great production challenges with respect to the quantity, quality, and stability of bispecific antibodies have hampered their wider clinical application and acceptance. In this review, we focus on these two major bispecific types and describe recent advances in the design, production, and quality of these molecules, which will enable this important class of biologics to reach their therapeutic potential.